
USD
$0.00
(0.00%
)At Close (As of Nov 28, 2025)
$5.63B
Market Cap
136.47
P/E Ratio
0.66
EPS
$93.25
52 Week High
$33.70
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $434M |
| Total Revenue | $434M |
| Cost Of Revenue | $3M |
| Costof Goods And Services Sold | $3M |
| Operating Income | $253M |
| Selling General And Administrative | $43M |
| Research And Development | $138M |
| Operating Expenses | $182M |
| Investment Income Net | - |
| Net Interest Income | $26M |
| Interest Income | $26M |
| Interest Expense | - |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $826K |
| Income Before Tax | $279M |
| Income Tax Expense | $4.2M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $275M |
| Comprehensive Income Net Of Tax | - |
| Ebit | $253M |
| Ebitda | $254M |
| Net Income | $275M |
| Field | Value (USD) |
|---|---|
| Total Assets | $745M |
| Total Current Assets | $592M |
| Cash And Cash Equivalents At Carrying Value | $97M |
| Cash And Short Term Investments | $97M |
| Inventory | - |
| Current Net Receivables | $168M |
| Total Non Current Assets | $153M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | - |
| Intangible Assets Excluding Goodwill | - |
| Goodwill | - |
| Investments | - |
| Long Term Investments | $140M |
| Short Term Investments | $322M |
| Other Current Assets | $4.2M |
| Other Non Current Assets | - |
| Total Liabilities | $69M |
| Total Current Liabilities | $47M |
| Current Accounts Payable | $1.6M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $510K |
| Total Non Current Liabilities | $22M |
| Capital Lease Obligations | $11M |
| Long Term Debt | - |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $11M |
| Other Current Liabilities | $24M |
| Other Non Current Liabilities | - |
| Total Shareholder Equity | $675M |
| Treasury Stock | - |
| Retained Earnings | -$341M |
| Common Stock | $1K |
| Common Stock Shares Outstanding | $65M |
| Field | Value (USD) |
|---|---|
| Gross Profit | $434M |
| Total Revenue | $434M |
| Cost Of Revenue | $3M |
| Costof Goods And Services Sold | $3M |
| Operating Income | $253M |
| Selling General And Administrative | $43M |
| Research And Development | $138M |
| Operating Expenses | $182M |
| Investment Income Net | - |
| Net Interest Income | $26M |
| Interest Income | $26M |
| Interest Expense | - |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $826K |
| Income Before Tax | $279M |
| Income Tax Expense | $4.2M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $275M |
| Comprehensive Income Net Of Tax | - |
| Ebit | $253M |
| Ebitda | $254M |
| Net Income | $275M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Protagonist Therapeutics, Inc. (PTGX) is a clinical-stage biopharmaceutical company specializing in the development of innovative peptide-based therapies targeting significant unmet medical needs, particularly in gastrointestinal disorders and hematological diseases. The company employs its proprietary peptide technology platform to advance a diverse pipeline of therapeutic candidates aimed at improving patient outcomes. Located in Newark, California, Protagonist is strategically focused on driving scientific innovation and addressing critical healthcare challenges, underpinned by a strong commitment to research and development. With a unique approach to peptide therapeutics, Protagonist is well-positioned to make a meaningful impact in the biopharmaceutical landscape.